Drug development is a time consuming, complex, risky and expensive venture. There is an increasing requirement to find ways to accelerate and reduce the cost of decision making so that only the best candidate molecules progress to the later stages of drug development.

Imanova is a translational research company that specialises in applying positron emission tomography (PET) and magnetic resonance imaging (MRI) scanning techniques to improve productivity in early drug development and to help improve disease understanding.

Established in 2011 Imanova was formed in an innovative alliance between the UK's Medical Research Council, Imperial College London, King's College London and University College London to act as a conduit between academia and industry.

Since inception, Imanova has completed over 50 clinical studies and is in a unique position to facilitate productive, mutually beneficial relationships between academia and industry.

10 April 2017
In the scope of the MIND MAPS programme Imanova has recently completed the implementation of three PET ligands to quantify the density of the molecular targets mitochondrial complex-1 (MC1), sigma-1 r...